Company intelligence / Profile preview

Proteinea

Ownership: Private
Development stage: Preclinical

Overview

Proteinea has developed proprietary AI models and computational tools to engineer next-generation antibodies with improved efficacy, safety, and convenience. Their platforms include the Ankh Protein Language Model for rapid design of novel proteins and an insect-based production system to lower costs. No clinical results have been published as of now; the company appears to be in preclinical/R&D stages with a strong technology foundation but no disclosed human trial data yet.

Therapeutic areas: Other
Modalities: Recombinant proteins (including antibodies)Engineered proteins/biotherapeuticsAntibody medicines
Industry: Biotech

Partnerships

Shorooq Partners (investor/supporter)

Beyond the preview

Go deeper on Proteinea.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proteinea.

Explore the full profile